These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31367013)

  • 1. SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC.
    Gao Q; Zhang G; Zheng Y; Yang Y; Chen C; Xia J; Liang L; Lei C; Hu Y; Cai X; Zhang W; Tang H; Chen Y; Huang A; Wang K; Tang N
    Cell Death Differ; 2020 Mar; 27(3):1086-1104. PubMed ID: 31367013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
    Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
    Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
    Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
    J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma.
    Lee D; Xu IM; Chiu DK; Leibold J; Tse AP; Bao MH; Yuen VW; Chan CY; Lai RK; Chin DW; Chan DF; Cheung TT; Chok SH; Wong CM; Lowe SW; Ng IO; Wong CC
    Hepatology; 2019 Apr; 69(4):1768-1786. PubMed ID: 30561826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arenobufagin regulates the p62-Keap1-Nrf2 pathway to induce autophagy-dependent ferroptosis in HepG2 cells.
    Yang Y; Liu C; Wang M; Cheng H; Wu H; Luo S; Zhang M; Duan X; Li Q
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4895-4909. PubMed ID: 38165425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DDX5 deficiency drives non-canonical NF-κB activation and NRF2 expression, influencing sorafenib response and hepatocellular carcinoma progression.
    Li Z; Kim W; Utturkar S; Yan B; Lanman NA; Elzey BD; Kazemian M; Yeo Y; Andrisani O
    Cell Death Dis; 2024 Aug; 15(8):583. PubMed ID: 39122708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone.
    Yang F; Li J; Deng H; Wang Y; Lei C; Wang Q; Xiang J; Liang L; Xia J; Pan X; Li X; Long Q; Chang L; Xu P; Huang A; Wang K; Tang N
    EMBO J; 2019 Aug; 38(15):e101964. PubMed ID: 31267557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway.
    Liu Y; Tao S; Liao L; Li Y; Li H; Li Z; Lin L; Wan X; Yang X; Chen L
    Nat Commun; 2020 Jan; 11(1):348. PubMed ID: 31953436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.
    Shi L; Wu L; Chen Z; Yang J; Chen X; Yu F; Zheng F; Lin X
    Cell Physiol Biochem; 2015; 35(6):2333-48. PubMed ID: 25896253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the Nrf2 response by oleanolic acid oxime morpholide (3-hydroxyiminoolean-12-en-28-oic acid morpholide) is associated with its ability to induce apoptosis and inhibit proliferation in HepG2 hepatoma cells.
    Narożna M; Krajka-Kuźniak V; Kleszcz R; Bednarczyk-Cwynar B; Szaefer H; Baer-Dubowska W
    Eur J Pharmacol; 2020 Sep; 883():173307. PubMed ID: 32668287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.
    Chen J; Jiang S; Shao H; Li B; Ji T; Staiculescu D; He J; Zhao J; Cai L; Liang X; Xu J; Cai X
    Sci China Life Sci; 2022 Oct; 65(10):1998-2016. PubMed ID: 35380342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma.
    Wang S; Cao K; Liao Y; Zhang W; Zheng J; Li X; Huang M; Zhong Y; Hu X; Chen D; Wang Y
    Oncogene; 2021 Jun; 40(25):4368-4383. PubMed ID: 34103686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines.
    Haque E; Śmiech M; Łuczyńska K; Bouchard MF; Viger R; Kono H; Pierzchała M; Taniguchi H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
    Elkateb AS; Nofal S; Ali SA; Atya HB
    Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
    Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
    Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
    Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
    J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ubiquitin E3 Ligase TRIM21 Promotes Hepatocarcinogenesis by Suppressing the p62-Keap1-Nrf2 Antioxidant Pathway.
    Wang F; Zhang Y; Shen J; Yang B; Dai W; Yan J; Maimouni S; Daguplo HQ; Coppola S; Gao Y; Wang Y; Du Z; Peng K; Liu H; Zhang Q; Tang F; Wang P; Gao S; Wang Y; Ding WX; Guo G; Wang F; Zong WX
    Cell Mol Gastroenterol Hepatol; 2021; 11(5):1369-1385. PubMed ID: 33482392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
    Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Takasu C; Miyazaki K; Shimada M
    PLoS One; 2021; 16(9):e0256755. PubMed ID: 34473785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.